HAMBURG, Germany, Oct. 16, 2013 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN: DE0005664809) announced today that its R&D Day 2013 will take place on 22 October 2013 in New York City, USA. At the meeting, Evotec will provide an overview of the Company's systematic, unbiased and comprehensive drug discovery infrastructures and its core disease areas.
Furthermore, Prof Dr Doug Melton will hold a presentation on regenerative medicine regarding beta cell function.
|Evotec R&D Day 2013|
|Date:||Tuesday, 22 October 2013, 11:30 am EDT|
|(04:30 pm GMT, 05:30 pm CET)|
|Venue:||New York, NY, USA|
|Presenter:||Dr Werner Lanthaler, Chief Executive Officer of Evotec|
|Dr Cord Dohrmann, Chief Scientific Officer of Evotec|
|Prof Dr Doug Melton, Xander University Professor in the Department of Stem Cell and Regenerative Biology at Harvard University, Harvard Stem Cell Institute Scientific Co-Director and Howard Hughes Medical Institute Investigator|
There will be a live webcast of this event:
About Evotec AG
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology and inflammation. Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca and Ono Pharmaceutical. In addition, the Company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Boehringer Ingelheim, MedImmune and Andromeda (Teva) in the field of diabetes, with Janssen Pharmaceuticals in the field of depression and with Roche in the field of Alzheimer's disease. For additional information please go to www.evotec.com.
FORWARD-LOOKING STATEMENTS — Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this report. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.
CONTACT: Gabriele Hansen Head of Corporate Communications +49.(0)40.560 81-255 +49.(0)40.560 81-222 Fax firstname.lastname@example.org Evotec AG Manfred Eigen Campus Essener Bogen 7 22419 Hamburg (Germany)Source:Evotec AG